UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions

Clinical cancer research, 2014-02, Vol.20 (3), p.617-630

2014

Volltextzugriff (PDF)

ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes

Molecular oncology, 2023-10, Vol.17 (10), p.2000-2016

2023

Volltextzugriff (PDF)

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling

PloS one, 2013-10, Vol.8 (10), p.e78881-e78881

2013

Volltextzugriff (PDF)

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers

Genome medicine, 2023-04, Vol.15 (1), p.28-28, Article 28

2023

Volltextzugriff (PDF)

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

Science (American Association for the Advancement of Science), 2019-11, Vol.366 (6466), p.714-723

2019

Volltextzugriff (PDF)

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma

British journal of cancer, 2017-02, Vol.116 (4), p.432-440

2017

Volltextzugriff (PDF)

Abstract PS7-23: Neoadjuvant and adjuvant therapy (NAT/AT) treatment patterns and clinical characteristics in a real-world cohort of US patients with HR+/HER2− early breast cancer (eBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS7-23-PS7-23

2021

Volltextzugriff (PDF)

Abstract P5-16-11: Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-16-11

2022

Volltextzugriff (PDF)

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study

Journal of clinical oncology, 2014-10, Vol.32 (30), p.3391-3399

2014

Volltextzugriff (PDF)

Abstract PD10-04: Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR+ breast cancer (M-HR+ BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD10-04-PD10-04

2022

Volltextzugriff (PDF)

Abstract NG16: Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.NG16-NG16

2020

Volltextzugriff (PDF)

Abstract P3-03-01: Double PIK3CA mutations in cis drive oncogene addiction and enhance sensitivity to PI3K alpha inhibitors in breast cancer

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P3-P3-03-01

2020

Volltextzugriff (PDF)

Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER

Journal of clinical oncology, 2018-06, Vol.36 (18_suppl), p.LBA1006-LBA1006

2018

Volltextzugriff (PDF)

Abstract PO1-20-02: MiRaDor: A proof-of-concept study of treatment efficacy by monitoring Minimal Residual Disease (MRD) using circulating tumor DNA (ctDNA) in hormone receptor-positive/HER2-negative (HR+/HER2-) early breast cancer (EBC)

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO1-20-02-PO1-20-02

2024

Volltextzugriff (PDF)

Abstract 5165: The genomic landscape and prognostic implications of somatic alterations in patients (pts) with ER+, HER2-, PIK3CA mutated (mut) advanced breast cancer treated with taselisib and fulvestrant

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5165-5165

2022

Volltextzugriff (PDF)

SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA- mutant tumors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS1119-TPS1119

2017

Volltextzugriff (PDF)

Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort

European urology, 2015-02, Vol.67 (2), p.310-318

2015

Volltextzugriff (PDF)

Abstract 5559: Exploratory analysis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) PIK3CA mutated (mut) advanced breast cancer (aBC) treated with taselisib (TAS) and/or fulvestrant (FUL) reveals increased CCNE2 expression with poor outcome to placebo (PBO) + FUL but not TAS + FUL in SANDPIPER

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.5559-5559

2023

Volltextzugriff (PDF)

A Novel Rab9 Effector Required for Endosome-to-TGN Transport

The Journal of cell biology, 1997-07, Vol.138 (2), p.283-290

1997

Volltextzugriff (PDF)

SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA- mutant tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS617-TPS617

2016

Volltextzugriff (PDF)

Qualitative assessment of the brief pain inventory (BPI) “pain at its worst in the last 24 hours” item to support assessment of pain as a clinical trial endpoint in metastatic castrate resistant prostate cancer (mCRPC) per FDA labeling standards

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e16018-e16018

2013

Volltextzugriff (PDF)

Abstract 2851: Cabozantinib (XL184) inhibits prostate tumor growth and bone lesion development

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2851-2851

2012

Volltextzugriff (PDF)

Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.9094-9094

2013

Volltextzugriff (PDF)

Abstract A233: Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A233-A233

2011

Volltextzugriff (PDF)

Specific requirements for the ER to Golgi transport of GPI-anchored proteins in yeast

Journal of cell science, 1997-11, Vol.110 ( Pt 21) (21), p.2703-2714

1997

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(35)
Webseiten
(1)

Sprache

Englisch
(36)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(15)
Humans
(10)
Cell Biology
(7)
Mutation
(6)
Kinases
(5)
Male
(5)
Oncology
(5)
Saccharomyces Cerevisiae Proteins
(5)
Tumors
(5)
Amino Acid Sequence
(4)
Animals
(4)
Biochemistry & Molecular Biology
(4)
Gtp Phosphohydrolases - Metabolism
(4)
Metastasis
(4)
Molecular Sequence Data
(4)
Saccharomyces Cerevisiae
(4)
Saccharomyces Cerevisiae - Metabolism
(4)
1-Phosphatidylinositol 3-Kinase
(3)
Aged
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions

ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma

Abstract PS7-23: Neoadjuvant and adjuvant therapy (NAT/AT) treatment patterns and clinical characteristics in a real-world cohort of US patients with HR+/HER2− early breast cancer (eBC)

Abstract P5-16-11: Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC)

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study

Abstract PD10-04: Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR+ breast cancer (M-HR+ BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC)

Abstract NG16: Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

Abstract P3-03-01: Double PIK3CA mutations in cis drive oncogene addiction and enhance sensitivity to PI3K alpha inhibitors in breast cancer

Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER

Abstract PO1-20-02: MiRaDor: A proof-of-concept study of treatment efficacy by monitoring Minimal Residual Disease (MRD) using circulating tumor DNA (ctDNA) in hormone receptor-positive/HER2-negative (HR+/HER2-) early breast cancer (EBC)

Abstract 5165: The genomic landscape and prognostic implications of somatic alterations in patients (pts) with ER+, HER2-, PIK3CA mutated (mut) advanced breast cancer treated with taselisib and fulvestrant

SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA- mutant tumors

Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort

A Novel Rab9 Effector Required for Endosome-to-TGN Transport

SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA- mutant tumors

Qualitative assessment of the brief pain inventory (BPI) “pain at its worst in the last 24 hours” item to support assessment of pain as a clinical trial endpoint in metastatic castrate resistant prostate cancer (mCRPC) per FDA labeling standards

Abstract 2851: Cabozantinib (XL184) inhibits prostate tumor growth and bone lesion development

Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT)

Abstract A233: Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone

Specific requirements for the ER to Golgi transport of GPI-anchored proteins in yeast

Suchergebnisse filtern